Sarah Bennett
Purevax® Feline Vaccines by Merial are the only feline vaccines developed without adjuvants, which are known to cause a rare but aggressive form of cancer in cats. Purevax® Feline 3 and 4 are modified live vaccines that protect cats from feline rhinotracheitis, calici, and panleukopenia viruses, with Feline 4 also providing protection against Chlamydia psittaci. They are recommended for cats 6 weeks of age and older, with a second dose administered 3 to 4 weeks later.
| Characteristics | Values |
|---|---|
| Brand | PureVAX® |
| Manufacturer | Merial |
| Type of Vaccine | Modified live vaccine |
| Diseases Protected Against | Feline rhinotracheitis, calici, panleukopenia viruses, and Chlamydia psittaci |
| Age of Administration | 6 weeks and older |
| Dosage | 1 mL |
| Administration Route | Subcutaneous or intramuscular injection |
| Revaccination Interval | 3 to 4 weeks after the primary vaccination |
| Storage | 2-7°C (35-45°F) |
| Precautions | Do not use chemicals to sterilize syringes and needles. Do not vaccinate pregnant cats. |
| Adjuvants | None |
Explore related products
What You'll Learn
PureVAX® is recommended for cats 6 weeks and older
PureVAX® is a range of feline vaccines developed by Merial. PureVAX® Feline 3 and PureVAX® Feline 4 are recommended for cats 6 weeks and older. PureVAX® Feline 3 contains a modified live virus that protects against feline rhinotracheitis, calici, and panleukopenia viruses. PureVAX® Feline 4 contains the same protection as Feline 3, with the addition of protection against Chlamydia psittaci.
The safety and effectiveness of both vaccines have been demonstrated through rigorous testing in susceptible cats. PureVAX® is unique in that it is the only feline vaccine developed without adjuvants, reducing the risk of injection-site reactions commonly associated with adjuvanted vaccines. This makes PureVAX® vaccines a safer option for cats and kittens.
PureVAX® Feline 3 and Feline 4 are administered through subcutaneous or intramuscular injection, with a dosage of 1 mL per dose. For primary vaccination, a second 1 mL dose is administered 3 to 4 weeks after the initial dose. Cats younger than 12 weeks of age should receive a single 1 mL dose every 3 to 4 weeks, with the last dose given at or over 12 weeks of age.
It is important to note that PureVAX® vaccines should not be administered to pregnant cats. In rare cases, the vaccines may cause side effects such as lethargy, fever, or inflammatory or hypersensitivity reactions. If these reactions occur, treatment with antihistamines, anti-inflammatories, and/or epinephrine may be necessary.
Hep B Vaccine: Understanding the Intricacies
You may want to see also
Explore related products
PureVAX® is the only feline vaccine without adjuvants
PureVAX® is the only feline vaccine developed without adjuvants, offering safer and more effective immunisation for cats and kittens. Adjuvants are added to vaccines to stimulate the immune system to react to the vaccine and increase its effectiveness. However, many adjuvanted vaccines have been scrutinised for potentially causing a rare but aggressive form of cancer (fibrosarcoma) in cats, affecting around 1 in 10,000 cats.
PureVAX®'s range of vaccines protects cats against rabies, feline leukemia virus (FeLV), rhinotracheitis, calicivirus, panleukopenia, and chlamydia. The Purevax Feline 4 vaccine, for example, contains a lyophilized suspension of modified live feline rhinotracheitis, calici, and panleukopenia viruses, as well as Chlamydia psittaci, propagated in a stable cell line. It is recommended for cats 6 weeks of age and older to prevent diseases caused by these viruses and aid in reducing the impact of Chlamydia psittaci.
PureVAX® vaccines utilise canarypox-vectored technology, providing robust protection while minimising the risk of injection-site reactions commonly associated with adjuvanted vaccines. This advanced vaccine technology triggers a strong immune response without the need for adjuvants. The absence of adjuvants minimises inflammation and post-vaccine reactions, making PureVAX® a safer choice for feline immunisation.
The PureVAX® Feline Vaccines are available in both single antigens and combination formulations, supporting complete feline health. The vaccines are administered by licensed veterinarians and are sold only to veterinarians, ensuring professional and safe immunisation for cats. By eliminating the potential risks associated with adjuvants, PureVAX® provides a unique and innovative approach to feline vaccination, prioritising the safety and well-being of cats while offering comprehensive protection against various diseases.
mRNA Vaccines: Better Protection Without the Pathogen Risk
You may want to see also
PureVAX® protects against feline rhinotracheitis, calici, and panleukopenia
PureVAX® is a registered trademark of Merial for feline vaccines developed without adjuvants, offering safer and more effective immunisation for cats and kittens. PureVAX® Feline 3 and Feline 4 are two such vaccines that protect against feline rhinotracheitis, calici, and panleukopenia viruses, among other diseases.
Feline rhinotracheitis is a viral infection that affects a cat's upper respiratory tract. It is highly contagious and can cause severe symptoms, including fever, sneezing, nasal discharge, and eye inflammation. The virus is spread through close contact with infected cats or exposure to contaminated objects.
Feline calicivirus is another highly contagious virus that affects the respiratory system of cats. It can cause a range of symptoms, from mild respiratory issues to more severe problems such as oral ulcers and limping. In some cases, a more severe strain called virulent systemic feline calicivirus (VS-FCV) can spread through a population, resulting in debilitating symptoms and a high mortality rate.
Feline panleukopenia, also known as feline distemper or FPV, is a highly contagious and potentially fatal virus. It causes severe gastrointestinal symptoms such as anorexia, vomiting, fever, and diarrhoea. The virus also attacks the bone marrow and lymph nodes, leading to a very low white blood cell count and compromising the cat's immune system.
PureVAX® Feline 3 and Feline 4 are designed to protect cats from these three diseases. Feline 3 is suitable for cats over eight weeks old, while Feline 4 can be administered to cats over six weeks old. Both vaccines contain a lyophilized suspension of modified live viruses, including feline rhinotracheitis, calici, and panleukopenia, propagated in a stable cell line, plus sterile water diluent. The safety and effectiveness of these vaccines have been demonstrated through rigorous testing, minimising inflammation and post-vaccine reactions.
Can I Ask for Proof of Vaccination?
You may want to see also
PureVAX® Feline 4 is an aid in the reduction of Chlamydia psittaci
PureVAX® Feline 4 is a vaccine that aids in the reduction of Chlamydia psittaci in cats. It is one of the Purevax® vaccines line developed by Merial, which are the only feline vaccines developed without adjuvants. PureVAX® Feline 4 is recommended for cats 6 weeks of age and older to prevent disease due to feline rhinotracheitis, calici, and panleukopenia viruses, as well as Chlamydia psittaci. The safety and immunogenicity of this product have been demonstrated through vaccination and challenge tests in susceptible cats.
PureVAX® Feline 4 contains a lyophilized suspension of modified live versions of the aforementioned viruses propagated in a stable cell line, plus sterile water diluent. To administer the vaccine, the lyophilized vaccine should be reconstituted with the accompanying liquid diluent. Then, a 1 mL (1 dose) should be injected subcutaneously or intramuscularly into healthy cats. For primary vaccination, a second 1 mL dose should be administered 3 to 4 weeks after the initial dose.
PureVAX® Feline 4 is unique in that it does not contain adjuvants, which are substances added to vaccines to enhance the immune response. By excluding adjuvants, PureVAX® vaccines offer safer and more effective immunization for cats and kittens while minimizing the risk of injection-site reactions commonly associated with adjuvanted vaccines. This is made possible by utilizing canarypox-vectored technology, which triggers a strong immune response without the need for adjuvants.
In addition to PureVAX® Feline 4, there are other vaccines in the PureVAX® line that aid in the prevention of various diseases in cats. These include PureVAX® Feline 3 (RCP), which protects against rhinotracheitis, calicivirus, and panleukopenia, and PureVAX® Feline 4 + Rabies, which combines the benefits of PureVAX® Feline 4 with protection against rabies. Overall, the PureVAX® line of vaccines provides comprehensive protection for feline health and well-being.
Vaccine Refusal: Your Child, Your Choice?
You may want to see also
PureVAX® is a registered trademark of Merial
The PureVAX® range includes vaccines for rabies, rhinotracheitis, calicivirus, panleukopenia, and chlamydia. PureVAX® Feline 3, for example, is recommended for the vaccination of healthy cats 6 weeks of age or older to prevent disease due to feline rhinotracheitis, calicivirus, and panleukopenia viruses. PureVAX® Feline 4, on the other hand, is also indicated for the reduction of disease due to Chlamydia psittaci in addition to the other three viruses.
PureVAX® Feline Rabies is another vaccine in the range, which is recommended for cats 12 weeks of age and older to prevent rabies. This vaccine is created using recombinant vectored technology, where a canarypox vector has been modified to produce the desired antigens to stimulate a protective immune response to rabies.
The PureVAX® vaccines are available in both single antigens and combination formulations, providing flexible options for veterinary professionals to support the complete health of cats and kittens.
Pneumococcal Vaccination: PCV21's Key Advantage
You may want to see also
Frequently asked questions
Purevax® is a feline vaccine that protects cats against feline leukemia virus (FeLV), rhinotracheitis, calicivirus, panleukopenia, and chlamydia. It is the only feline vaccine developed without adjuvants, which have been linked to a rare but aggressive form of cancer in cats.
Purevax® offers safer and effective immunization for cats and kittens by minimizing the risk of injection-site reactions commonly associated with adjuvanted vaccines. It is also the only vaccine that follows the American Association of Feline Practitioners (AAFP) Vaccine Guidelines, which recommends core vaccines (rabies vaccine, FVRCP vaccine) to all cats.
Purevax® is administered by reconstituting the lyophilized vaccine with the accompanying liquid diluent and then aseptically injecting 1 mL (1 dose) subcutaneously or intramuscularly into healthy cats aged 6 weeks and older. A second 1 mL dose is given 3 to 4 weeks later for primary vaccination. It should be stored at 2-7°C (35-45°F) and used immediately after reconstitution.
Yes, Purevax® should not be administered to pregnant cats. In rare instances, the vaccine may cause lethargy, fever, and inflammatory or hypersensitivity reactions. Treatment for these reactions may include antihistamines, anti-inflammatories, and/or epinephrine. A FeLV test is strongly recommended prior to vaccination to ensure the cat is healthy.
